A61K 2239/27
Characterized by targeting or presenting multiple antigens
Official title: characterized by targeting or presenting multiple antigens
A61K2239/27 (Characterized by targeting or presenting multiple antigens) appears on 223 US grants and 786 published applications in this corpus.
Search patents in A61K- Granted patents
- 223
- Published applications
- 786
- Assignees
- 311
- Inventors
- 1,666
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 2 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 3 |
| 2010 | 1 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 2 |
| 2014 | 1 | 4 |
| 2015 | 0 | 5 |
| 2016 | 2 | 7 |
| 2017 | 6 | 14 |
| 2018 | 1 | 34 |
| 2019 | 7 | 25 |
| 2020 | 14 | 56 |
| 2021 | 16 | 76 |
| 2022 | 23 | 79 |
| 2023 | 31 | 99 |
| 2024 | 38 | 168 |
| 2025 | 45 | 118 |
| 2026 | 38 | 91 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof6 Oct 2026US 12,753,221 B2Abelzeta Inc.
- Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy22 Sep 2026US 12,742,152 B2Angeles Therapeutics, Inc.
- Switch receptors1 Oct 2026US 2026/0295042 A1Hoffmann-La Roche Inc.
- Viral vectors for glioblastoma cell therapy24 Sep 2026US 2026/0284109 A1
- Coreceptor chimeric antigen receptor24 Sep 2026US 2026/0284111 A1
- Disruption of telocyte activity10 Sep 2026US 2026/0263514 A1
- Il-9r signaling compositions and methods10 Sep 2026US 2026/0263516 A1The Regents of the University of California
Most cited
By later US patents
- Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy108US 9,745,368 B2Novartis AG · 2017
- Compositions, methods, and computer systems related to making and administering modified T cells107US 9,499,855 B2Elwha LLC · 2016
- Bispecific chimeric antigen receptors and encoding polynucleotides thereof92US 9,447,194 B2Seattle Children's Hospital · 2016
- Activated dual specificity lymphocytes and their methods of use32US 7,723,111 B2The United States of America as represented by the Department of Health and Human Services · 2010
- Binding-triggered transcriptional switches and methods of use thereof31US 9,670,281 B2The Regents of the University of California · 2017